Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 3:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 711 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Atopic Clear all
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Topically Applied DS107 Cream in Mild to Moderate Atopic Dermatitis Patients (AD)

NCT02925793
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
DS107, Vehicle cream
Drug · Other
Lead sponsor
DS Biopharma
Industry
Eligibility
18 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
East Windsor, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Oct 27, 2026, 3:57 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

NCT06461897
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Upadacitinib, Dupilumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
2 Years to 11 Years
Enrollment
699 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
31
States / cities
Little Rock, Arkansas • Palo Alto, California • Sacramento, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 27, 2026, 3:57 AM EDT
Terminated Not applicable Interventional

The Role of Bathing Additives in the Treatment of Pediatric Atopic Dermatitis

NCT03775590
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Water, Bleach, Acetic acid
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
6 Months to 17 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
2
States / cities
Rochester, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Oct 27, 2026, 3:57 AM EDT
Completed Not applicable Interventional Results available

Team-Based Connected Health (TCH) to Improve Clinical Outcomes and Access in Atopic Dermatitis

NCT03981926
View directory record Official record
Conditions
Atopic Dermatitis Eczema, Atopic Dermatitis, Eczema
Interventions
Team-Based Connected Health (TCH)
Other
Lead sponsor
University of Southern California
Other
Eligibility
1 Year and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 27, 2026, 3:57 AM EDT
Terminated Not applicable Interventional

Dilute Bleach Baths in Pediatric Patients With Atopic Dermatitis

NCT01286220
View directory record Official record
Conditions
Moderate to Severe Atopic Dermatitis
Interventions
Dilute bleach baths, Water
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
2 Years to 17 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 20, 2020 · Synced Oct 27, 2026, 3:57 AM EDT
Completed Phase 2 Interventional Results available

Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

NCT01859988
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
25
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2017 · Synced Oct 27, 2026, 3:57 AM EDT
Not yet recruiting No phase listed Observational

An Observational Study of Patients With Dermatologic Disease

NCT07748169
View directory record Official record
Conditions
Vitiligo, Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa (HS)
Interventions
Not listed
Lead sponsor
Target PharmaSolutions, Inc.
Industry
Eligibility
Not listed
Enrollment
2,000,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2041
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 27, 2026, 3:57 AM EDT
Completed Not applicable Interventional Results available

Comparing Cetaphil Restoraderm System Versus Standard Skin Care in Infants

NCT01375205
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Cetaphil Restoraderm, Standard of Care
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
1 Day to 3 Weeks
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Oct 27, 2026, 3:57 AM EDT
Recruiting No phase listed Observational

NHALES (Natural History of Asthma With Longitudinal Environmental Sampling)

NCT02327897
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 60 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2030
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 27, 2026, 3:57 AM EDT
Completed Not applicable Interventional Results available

Human Testing of an Over-the-Counter (OTC) Cream in Children With Eczema

NCT01326910
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Colloidal Oatmeal, Topical Cream
Drug · Device
Lead sponsor
Johnson & Johnson Consumer Products Company Division of Johnson & Johnson Consumer Companies, Inc.
Industry
Eligibility
6 Months to 18 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
St. Petersburg, Florida • Miamiville, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 3, 2012 · Synced Oct 27, 2026, 3:57 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis

NCT06863961
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Afimkibart, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
21
States / cities
Fremont, California • Los Angeles, California • Fort Myers, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 27, 2026, 3:57 AM EDT
Not listed No phase listed Observational

A Prospective Sample Collection Study Using Non-invasive Methods to Investigate Biomarkers in AD Patients

NCT04699695
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Biologic therapy versus no biologic therapy
Other
Lead sponsor
DermTech
Other
Eligibility
1 Year and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
New York, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 27, 2026, 3:57 AM EDT
Completed Phase 4 Interventional Results available

Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis

NCT03293030
View directory record Official record
Conditions
Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema, Atopic Dermatitis and Related Conditions
Interventions
Dupilumab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 27, 2026, 3:57 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis

NCT04162769
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Etrasimod 1 mg, Etrasimod 2 mg, Etrasimod matching placebo
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
35
States / cities
Tucson, Arizona • Canoga Park, California • Fountain Valley, California + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2022 · Synced Oct 27, 2026, 3:57 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Pimecrolimus Cream 1% (Elidel®) and Medicated Device Cream (EletoneTM) in the Treatment and Maintenance of Atopic Dermatitis.

NCT01177566
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
pimecrolimus, topical medical device
Drug · Device
Lead sponsor
Emer, Jason, M.D.
Individual
Eligibility
2 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2010 · Synced Oct 27, 2026, 3:57 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

NCT06389136
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Upadacitinib 15mg Dose, Dupilumab 300mg Dose, Upadacitinib 30mg Dose
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 63 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
84
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fayetteville, Arkansas + 70 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 27, 2026, 3:57 AM EDT
Completed Phase 2 Interventional Results available

Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis

NCT05186805
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tapinarof cream, 1%
Drug
Lead sponsor
Organon and Co
Industry
Eligibility
2 Years to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
9
States / cities
Thousand Oaks, California • Centennial, Colorado • Coral Gables, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 27, 2026, 3:57 AM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis

NCT02945657
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
MM36 topical ointment, 1%
Drug
Lead sponsor
Medimetriks Pharmaceuticals, Inc
Industry
Eligibility
2 Years to 17 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
10
States / cities
Fremont, California • Irvine, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Oct 27, 2026, 3:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome

NCT01428297
View directory record Official record
Conditions
Healthy Volunteers, Atopic Dermatitis, Netherton Syndrome
Interventions
BPR277 ointment (controlled application), Placebo (Vehicle), BPR277 ointment, BPR277
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
3
States / cities
New Haven, Connecticut • St Louis, Missouri • Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 27, 2026, 3:57 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)

NCT04921969
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib, Vehicle Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
2 Years to 11 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
64
States / cities
Birmingham, Alabama • Hoover, Alabama • Gilbert, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 27, 2026, 3:57 AM EDT
Completed Phase 1 Interventional

A Study of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis

NCT03379311
View directory record Official record
Conditions
Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, Perennial Allergic Conjunctivitis
Interventions
AK002
Drug
Lead sponsor
Allakos Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
8
States / cities
Palo Alto, California • Edgewater, Florida • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2019 · Synced Oct 27, 2026, 3:57 AM EDT
Completed Phase 3 Interventional Results available

Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel® Cream, 1% in Mild to Moderate Atopic Dermatitis

NCT03107611
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus Cream, 1%, Placebo Cream
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
8 Years and older
Enrollment
654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
25
States / cities
Boynton Beach, Florida • Coral Gables, Florida • Miami, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Oct 27, 2026, 3:57 AM EDT
Completed Phase 2 Interventional

A Study in Subjects With Moderate Atopic Dermatitis

NCT03175354
View directory record Official record
Conditions
Atopic Dermatitis, Eczema, Atopic
Interventions
ALX-101 Gel 1.5% and ALX-101 Gel Vehicle, ALX-101 Gel 5% and ALX-101 Gel Vehicle
Drug
Lead sponsor
Ralexar Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
35
States / cities
Anniston, Alabama • Birmingham, Alabama • Laguna Hills, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Oct 27, 2026, 3:57 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)

NCT03346434
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Dupilumab, Matching placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
6 Months to 5 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
33
States / cities
Birmingham, Alabama • Gilbert, Arizona • Long Beach, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Oct 27, 2026, 3:57 AM EDT